Medicare Enrolled
Dr. Bashar Saad, MD
Endocrinology · San Dimas, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Saad from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Saad?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Saad
Dr. Bashar Saad is an endocrinology specialist in San Dimas, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Saad performed 2,720 Medicare services across 1,590 unique beneficiaries.
Between the years covered by Open Payments, Dr. Saad received a total of $153,872 from 68 pharmaceutical and/or device companies across 2089 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in endocrinology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Saad is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 24% volume in CA
$153,872 industry payments
Medicare Practice Summary
Medicare Utilization ↗2,720
Medicare services
Top 24% in CA for endocrinology
1,590
Unique beneficiaries
$101
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~143 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,855 | $99 | $244 |
| New patient office visit, complex (60-74 min) | 159 | $175 | $470 |
| Ultrasound of head and neck soft tissue This procedure uses sound waves to create images of the soft tissues in the head and neck area. It allows for the visualization of structures beneath the skin without using radiation. |
151 | $93 | $334 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
139 | $129 | $316 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
99 | $71 | $192 |
| Continuous glucose monitoring with interpretation This procedure involves monitoring blood sugar levels in tissue fluid using a sensor placed under the skin, along with the interpretation and reporting of the results. |
80 | $28 | $101 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
79 | $66 | $195 |
| Ultrasound-guided fine needle aspiration biopsy, first lesion A biopsy procedure where a thin needle is used to collect tissue samples from a growth, guided by ultrasound imaging. This code applies to the first lesion or mass sampled during the session. |
68 | $116 | $350 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
68 | $145 | $540 |
| Ultrasound-guided fine needle aspiration biopsy, each additional growth This procedure involves using ultrasound guidance to perform a fine needle aspiration biopsy on an additional growth during the same session. |
22 | $51 | $188 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$153,872
Total received (2018-2024)
Avg $21,982/year across 7 years
Top 4% in CA for endocrinology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
68
Companies
2,089
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$129,232 (84.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$24,641 (16.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$12,267
2023
$17,833
2022
$12,529
2021
$16,778
2020
$11,948
2019
$43,403
2018
$39,114
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Boehringer Ingelheim Pharmaceuticals, Inc.
$4,484
Lilly USA, LLC
$3,108
Amgen Inc.
$665
Novo Nordisk Inc
$514
Abbott Laboratories
$492
Dexcom, Inc.
$448
Mannkind Corporation
$336
Xeris Pharmaceuticals, Inc.
$274
CeQur Corporation
$193
Insulet Corporation
$156
SANOFI-AVENTIS U.S. LLC
$149
Madrigal Pharmaceuticals
$141
Esperion Therapeutics, Inc.
$133
RECORDATI_RARE_DISEASES_INC.
$132
Tandem Diabetes Care, Inc.
$113
Radius Health, Inc.
$112
ABBVIE INC.
$93
Antares Pharma, Inc.
$90
BETA BIONICS, INC.
$85
Tolmar, Inc.
$79
Ascensia Diabetes Care Us Inc.
$75
Lexicon Pharmaceuticals, Inc.
$55
Novartis Pharmaceuticals Corporation
$53
Bayer Healthcare Pharmaceuticals Inc.
$52
Embecta Corp.
$48
Alexion Pharmaceuticals, Inc.
$48
Neurocrine Biosciences, Inc.
$34
PFIZER INC.
$27
Alvogen Inc
$24
Kyowa Kirin, Inc.
$21
Ascendis Pharma Inc
$19
Acella Pharmaceuticals, LLC
$16
Top 3 companies account for 67.3% of 2024 payments
All-time payments by company (2018-2024) ›
Boehringer Ingelheim Pharmaceuticals, Inc.
$67,602
SANOFI-AVENTIS U.S. LLC
$25,014
Lilly USA, LLC
$21,467
Janssen Pharmaceuticals, Inc
$16,005
Novo Nordisk Inc
$3,268
Amgen Inc.
$2,660
Abbott Laboratories
$2,215
Dexcom, Inc.
$1,882
Mannkind Corporation
$1,644
AstraZeneca Pharmaceuticals LP
$949
MannKind Corporation
$898
Xeris Pharmaceuticals, Inc.
$707
Novartis Pharmaceuticals Corporation
$703
Antares Pharma, Inc.
$590
Tandem Diabetes Care, Inc.
$567
Insulet Corporation
$523
Horizon Therapeutics plc
$470
Amarin Pharma Inc.
$451
Embecta Corp.
$448
CeQur Corporation
$346
Medtronic, Inc.
$343
Bayer Healthcare Pharmaceuticals Inc.
$323
Becton, Dickinson and Company
$302
RECORDATI_RARE_DISEASES_INC.
$260
Esperion Therapeutics, Inc.
$259
Radius Health, Inc.
$252
AbbVie Inc.
$227
Kyowa Kirin, Inc.
$223
Bigfoot Biomedical Inc
$222
DEXCOM, INC.
$203
AbbVie, Inc.
$170
Alexion Pharmaceuticals, Inc.
$165
Stryker Corporation
$161
Merck Sharp & Dohme Corporation
$160
Medtronic MiniMed, Inc.
$151
Supernus Pharmaceuticals, Inc.
$151
Madrigal Pharmaceuticals
$141
GRT US Holding, Inc.
$137
Corcept Therapeutics
$132
IBSA Pharma Inc.
$132
Tolmar, Inc.
$113
Allergan, Inc.
$103
ABBVIE INC.
$93
BETA BIONICS, INC.
$85
Lexicon Pharmaceuticals, Inc.
$80
Bayer HealthCare Pharmaceuticals Inc.
$79
Regeneron Healthcare Solutions, Inc.
$78
Ascensia Diabetes Care Us Inc.
$75
Senseonics, Incorporated
$62
Alvogen Inc
$62
PFIZER INC.
$61
Acella Pharmaceuticals, LLC
$45
LIFESCAN, INC.
$43
Ascensia Diabetes Care US Inc.
$41
Aegerion Pharmaceuticals, Inc.
$40
LifeScan, Inc.
$40
Kowa Pharmaceuticals America, Inc.
$40
Neurocrine Biosciences, Inc.
$34
Merck Sharp & Dohme LLC
$34
Currax Pharmaceuticals LLC
$26
Companion Medical, Inc.
$26
Ascendis Pharma Inc
$19
Vertiflex, Inc.
$16
Nevro Corp.
$15
Shire North American Group Inc
$14
Echosens North America, Inc.
$14
Zealand Pharma US, Inc.
$12
Retrophin, Inc.
$2
Top 3 companies account for 74.1% of all-time payments
Associated products mentioned in payments ›
(820) Cholbam · AFREZZA · Aimovig · Androgel · BAQSIMI · BASAGLAR · BD NANO · BD Nano · BD Nano 2nd Gen Pen Needle · BELSOMRA · BYDUREON · CONTRAVE · CeQur Simplicity · Corlanor · Crysvita · DEXCOM CGM · DEXCOM G6 CGM SYSTEM · DEXCOM G6 TRANSMITTER · Dexcom CGM · Dexcom G6 Transmitter · ENTRESTO · EVENITY · EVERSENSE E3 SENSOR KIT - RETAIL · Eversense · FARXIGA · FORTEO · FREESTYLE LIBRE · FREESTYLE LIBRE 2 · FREESTYLE LIBRE 3 · FibroScan · FreeStyle Libre · FreeStyle Libre blood glucose Flash Monitoring System · GLYXAMBI · GVOKE HYPOPEN · GVOKE PFS · HUMALOG · HUMULIN · HUMULIN R 500 · INPEN SMART INSULIN DELIVERY SYSTEM · INVOKANA · InPen · Inpefa · JANUVIA · JARDIANCE · JATENZO · JUXTAPID · KEVEYIS · Kerendia · Korlym · LEQVIO · LINZESS · LYUMJEV · Levemir · Livalo · MAKO · MINIMED 770G · MINIMED 780G · MOUNJARO · Minimed 630G · NATPARA (PARATHYROID HORMONE) · NEXLETOL · NOCDURNA · NP Thyroid 60 · OT Verio Flex Starter Kit · OTREXUP · Omnipod · OneTouch Verio Reflect · Otrexup · Ozempic · PAXLOVID · PRALUENT · PRALUENT ALIROCUMAB INJECTION · Prolia · Qutenza · RECORLEV · RESMETIROM · RYBELSUS · Repatha · Rybelsus · SIGNIFOR LAR · SOLIQUA · SOLIQUA 100/33 · SOMAVERT · STEGLATRO · STRENSIQ · SYNJARDY · SYNTHROID · Senza · Strensiq · Superion ISS · Synthroid · TEPEZZA · TERIPARATIDE · TLANDO · TOUJEO · TRADJENTA · TRULICITY · TZIELD · Tirosint · Tresiba · Tymlos · UBRELVY · UNITY DIABETES MANAGEMENT SYSTEM · V-GO DISPOSABLE INSULIN DELIVERY · Vascepa · Victoza · Wegovy · XARELTO · XYOSTED · iLet Bionic Pancreas · t-slim insulin pump · t:slim X2 Insulin Pump with Control-IQ · t:slim X2 insulin pump
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (84%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in endocrinology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 4% for endocrinology in CA.
Geographic Context
Endocrinologists within 10 mi
108
Per 100K population
1.1
County median income
$87,760
Nearest hospital
SAN DIMAS COMMUNITY HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Saad is a clinical cardiology specialist, with above-average Medicare volume (top 24% in CA), with speaking/promotional industry engagement in the top 4% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Saad experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Saad performed 1,855 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Saad receive payments from pharmaceutical companies?
Yes. Dr. Saad received a total of $153,872 from 68 companies across 2,089 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Saad's costs compare to other endocrinologists in San Dimas?
Dr. Saad's average Medicare payment per service is $101. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Saad) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Endocrinology
Common procedures, typical costs, and what industry payments mean in endocrinology.
Same specialty & city
Endocrinologists in San Dimas
Browse endocrinologists in San Dimas ranked by procedure volume and transparency data.
Highest volume
Top Endocrinologists in CA
Endocrinologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Endocrinologists in CA
Which CA endocrinologists receive the most from drug and device companies.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
By company
SANOFI-AVENTIS U.S. LLC Payments to Doctors
See all physicians who received payments from SANOFI-AVENTIS U.S. LLC.
By company
Lilly USA, LLC Payments to Doctors
See all physicians who received payments from Lilly USA, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology